Moreover, a study indicated that CDKN3 expression was negatively correlated with tumor staging, and CDKN3 inhibition promoted hepatocellular cancer cell survival and cisplatin tolerance [49]. Here, CDKN3 is linked to hepatocellular carcinoma.